Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Sionna Therapeutics (NASDAQ: SION), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in the Goldman Sachs 46th Annual Healthcare Conference. The company's management will engage in a fireside chat on June 11th, 2025, at 8:00 a.m. ET in Miami, Florida. The presentation will be accessible via live webcast on Sionna's investor relations website, with a replay available afterward. Sionna's mission centers on developing novel medicines that aim to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, potentially transforming the current CF treatment landscape.

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46^th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11^th 2025 at 8:00 a.m. ET.

A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.

About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com. 

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com

Investor Contact
Juliet Labadorf
ir@sionnatx.com

FAQ

When is Sionna Therapeutics (SION) presenting at the Goldman Sachs Healthcare Conference 2025?

Sionna Therapeutics will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11th, 2025, at 8:00 a.m. ET in Miami, Florida.

What is Sionna Therapeutics' (SION) main focus in drug development?

Sionna Therapeutics focuses on developing novel medicines to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein for treating cystic fibrosis.

How can investors access Sionna Therapeutics' (SION) Goldman Sachs conference presentation?

Investors can access the live webcast of the presentation on the 'Events' page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will be available after the event.

What type of company is Sionna Therapeutics (SION)?

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment paradigm for cystic fibrosis through novel medicines.